Home › Arthritis › NCT06647134
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria The criteria are: * Patients aged 18 years and above * English (conversational level) speaking, with the ability to give informed consent * Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy Exclusion Criteria * Acutely life-threatening or worsening cancer * Hearing impairment functionally limiting participation in verbal interview
About the study
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Sponsor: M.D. Anderson Cancer Center · Participants: 20 · Started: Sep 11, 2024
Contact the study team
- Y. Jeff Li, MD · Phone: 713-409-1565
Official record on ClinicalTrials.gov — NCT06647134
Locations in the U.S.
| Texas | MD Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.